Cancer-associated systemic inflammation is strongly linked to poor disease outcome in
patients with cancer,. For most human epithelial tumour types, high systemic neutrophil-to …

A better understanding of the features that define the interaction between cancer cells and
immune cells is important for the development of new cancer therapies. However, focus is …

The heterogeneity of cellular states in cancer has been linked to drug resistance, cancer
progression and the presence of cancer cells with properties of normal tissue stem cells …

Melanoma treatment is being revolutionized by the development of effective
immunotherapeutic approaches,. These strategies include blockade of immune-inhibitory …

Disseminated cancer cells from primary tumours can seed in distal tissues, but may take
several years to form overt metastases, a phenomenon that is termed tumour dormancy …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with high resistance to
therapies. Inflammatory and immunomodulatory signals co-exist in the pancreatic tumour …

Despite progress in the development of drugs that efficiently target cancer cells, treatments
for metastatic tumours are often ineffective. The now well-established dependency of cancer …

Understanding of the factors governing immune responses in cancer remains incomplete,
limiting patient benefit. In this study, we used mass cytometry to define the systemic immune …

On the basis of data published in Nature Medicine, the research groups of Zitvogel and
Kroemer have hypothesized that the adaptive immune system dictates the therapeutic …

Cancer genome sequencing studies indicate that a single breast cancer typically harbours
multiple genetically distinct subclones,,,. As carcinogenesis involves a breakdown in the cell …